Ascendia

  MARKET NEWS

Centrix Pharma Solutions and University of Sussex partner to advance data-driven pharmaceutical development
McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
Hovione Completes Expansion of Loures Tablet Manufacturing Center Adding Commercial-Scale Batch Tableting Capacity
Aptar Active Material Science first use of Activ-Film technology with a commercialized capsule-based Dry Powder Inhalation (DPI) drug product.
FDA Approves IMAAVY (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia

  EXPERT CONTENT & RESOURCES

 

SPECTROSCOPY - High-Precision Tunable Laser Spectroscopy: A “Library-Based” Approach to Quantitative Bioprocess Analytics

SPECTROSCOPY - High-Precision Tunable Laser Spectroscopy: A “Library-Based” Approach to Quantitative Bioprocess Analytics

The accuracy and speed of analytical measurements play a critical role in biopharmaceutical development and manufacturing. In particular, the ability to quantify both active pharmaceutical ingredients (APIs) and formulation excipients – such as buffers, amino acids, sugars, and surfactants – is essential for ensuring product quality, process consistency, and regulatory compliance.

Pharmaceutical cold storage market growth chart.

COLD CHAIN SUSTAINABILITY - Cold Front: The Growing Need for Controlling Cold Storage Energy Costs

The pharmaceutical and biotech industries are not only one of the most prominent users of cold storage solutions today but are also one of the market’s most important growth drivers. Several factors, including the rise of temperature sensitive drugs, growing energy prices, and increasing regulatory scrutiny are inevitably compelling the pharmaceutical industry to consider its use of the global cold chain with sustainability in mind.

Abbvie Logo

Four Myths About Embedded CMOs, Busted

Are your perceptions of the CMO marketplace serving your drug program—or holding it back? If you’re looking for a contract manufacturer to bring your therapy to market, you’re far from alone. Demand for manufacturing services is shaping the pharma Contract Manufacturing Industry, with analysts predicting a growth rate of nearly 7% per year until 2028. In such a competitive market, how should a project sponsor navigate the choice between one CMO and another? To find the answer, many sponsors begin by distinguishing between typical stand-alone CMOs and an embedded CMO that operates under a parent company—AbbVie, in the case of AbbVie Contract Manufacturing (AbbVie).

Monoclonal vs Polyclonal Antibody Production – Explained Step by Step

Monoclonal vs Polyclonal Antibody Production – Explained Step by Step

Antibody-based therapeutics have reshaped modern medicine. With demand soaring, choosing the appropriate production path can save months and millions.

According to Grand View Research, the global therapeutic antibody market will surpass US $2.21 billion by 2030.

Based on our expertise in monoclonal antibody production, let’s take a look at how each antibody type is produced, contrasts their timelines, costs, and use-cases, and ends with clear next steps to keep your project moving.

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

Mastering Analytics: LC-MS Analysis of Oligonucleotide Drugs

Mastering Analytics: LC-MS Analysis of Oligonucleotide Drugs

  COMPANY PROFILE

PCI Pharma Services provides world-class solutions through intelligence, ingenuity and innovation, together, delivering life-changing therapies. With integration from inception and quality at our core, PCI’s development, manufacturing, clinical trial services, advanced drug delivery and packaging capabilities combine to minimize time-to-market and maximize opportunities for commercial success. PCI serves as an extension of its customers’ value chains, toward the shared goal of improving patients’ lives.

Click here for more.

 

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND - Heat Without Harm: The Reality of Hot Melt Extrusion Webinar

WEBINAR ON DEMAND - Heat Without Harm: The Reality of Hot Melt Extrusion Webinar

In a 2025 industry survey (1), 76% of respondents selected ‘risk of thermal degradation’ as a source of hesitation to pursue hot melt extrusion (HME). Concerns about heat-sensitive APIs frequently lead development teams to rule out HME early — …

WHITEPAPER - Container Closure Integrity Issues in Cell & Gene Therapy Products

WHITEPAPER - Container Closure Integrity Issues in Cell & Gene Therapy Products

The cell and gene therapy (CGT) product market is expected to grow at a very high rate of around 20-30% per year over the next 10 years. Increasing number of approvals, expansion of target diseases, accelerated investment and innovation, and …

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.

In a recent panel discussion, GlobalData’s Director …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 9 – Bioavailability
September 16 – Capsules
September 23 – Analytical Testing
September 30 – Formulation Development

Company Profiles: